GlassScriptPhysician profile
Hassan Borghei
NPI 1093913550
$7,214.21
in general payments reported to CMS, 2019-2025
30 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $744 · 2021: $1,264 · 2022: $1,150 · 2023: $1,761 · 2024: $1,153 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,310 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,310.34 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,642.94 | 2019-2025 | Linzess, Viberzi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $694.92 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $647.15 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $517.54 | 2020-2024 | Entyvio |
| Janssen Biotech, INC. | $503.17 | 2022-2024 | Stelara, Simponi, Simponi Aria |
| Nestle Healthcare Nutrition INC. | $322.50 | 2021-2022 | |
| Gilead Sciences, INC. | $228.60 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $219.10 | 2024-2025 | Voquezna |
| Pfizer INC. | $167.70 | 2022-2024 | |
| Genzyme Corporation | $164.48 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $157.38 | 2019-2024 | Ocaliva |
| Vivus LLC | $134.29 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $123.71 | 2022-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $115.92 | 2023 | Zeposia |
| Ucb, INC. | $100.70 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $62.13 | 2025 | Spyglass, Autocap Rx |
| Ardelyx, INC. | $44.42 | 2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $41.10 | 2020-2022 | |
| Evoke Pharma, INC. | $37.31 | 2023 | Gimoti |
| Lilly USA, LLC | $33.72 | 2024 | Omvoh |
| Qol Medical, LLC | $32.00 | 2022 | |
| Ironwood Pharmaceuticals, INC | $31.87 | 2019 | |
| Redhill Biopharma INC. | $30.70 | 2021 | |
| Allergan, INC. | $30.44 | 2019 | |
| Merz Pharmaceuticals, LLC | $25.10 | 2024 | Xeomin |
| Novo Nordisk INC | $24.76 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $24.45 | 2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $22.75 | 2023 | |
| Ferring Pharmaceuticals INC. | $17.51 | 2020 | |
| Aimmune Therapeutics, INC. | $15.85 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hassan Borghei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.